173 related articles for article (PubMed ID: 20107010)
21. Using a Human Challenge Model of Infection to Measure Vaccine Efficacy: A Randomised, Controlled Trial Comparing the Typhoid Vaccines M01ZH09 with Placebo and Ty21a.
Darton TC; Jones C; Blohmke CJ; Waddington CS; Zhou L; Peters A; Haworth K; Sie R; Green CA; Jeppesen CA; Moore M; Thompson BA; John T; Kingsley RA; Yu LM; Voysey M; Hindle Z; Lockhart S; Sztein MB; Dougan G; Angus B; Levine MM; Pollard AJ
PLoS Negl Trop Dis; 2016 Aug; 10(8):e0004926. PubMed ID: 27533046
[TBL] [Abstract][Full Text] [Related]
22. Terminal Deoxynucleotidyl Transferase Is Not Required for Antibody Response to Polysaccharide Vaccines against Streptococcus pneumoniae and Salmonella enterica Serovar Typhi.
Belde V; Cravens MP; Gulandijany D; Walker JA; Palomo-Caturla I; Alugupalli AS; Sandilya VK; Mahmoud T; Bäumler AJ; Kearney JF; Alugupalli KR
Infect Immun; 2018 Sep; 86(9):. PubMed ID: 29967094
[TBL] [Abstract][Full Text] [Related]
23. IgA and IgG1 Specific to Vi Polysaccharide of
Dahora LC; Jin C; Spreng RL; Feely F; Mathura R; Seaton KE; Zhang L; Hill J; Jones E; Alam SM; Dennison SM; Pollard AJ; Tomaras GD
Front Immunol; 2019; 10():2582. PubMed ID: 31781100
[TBL] [Abstract][Full Text] [Related]
24. Multicenter study for the evaluation of the antibody response against salmonella typhi Vi vaccination (EMPATHY) for the diagnosis of Anti-polysaccharide antibody production deficiency in patients with primary immunodeficiency.
Sánchez-Ramón S; de Gracia J; García-Alonso AM; Rodríguez Molina JJ; Melero J; de Andrés A; García Ruiz de Morales JM; Ferreira A; Ocejo-Vinyals JG; Cid JJ; García Martínez JM; Lasheras T; Vargas ML; Gil-Herrera J; García Rodríguez MC; Castañer JL; González Granado LI; Allende LM; Soler-Palacin P; Herráiz L; López Hoyos M; Bellón JM; Silva G; Gurbindo DM; Carbone J; Rodríguez-Sáinz C; Matamoros N; Parker AR; Fernández-Cruz E;
Clin Immunol; 2016 Aug; 169():80-84. PubMed ID: 27236002
[No Abstract] [Full Text] [Related]
25. Isotypes of human vaccinal antibodies to the Vi capsular polysaccharide of Salmonella typhi.
Brugier JC; Barra A; Schulz D; Preud'homme JL
Int J Clin Lab Res; 1993; 23(1):38-41. PubMed ID: 8477090
[TBL] [Abstract][Full Text] [Related]
26. The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children.
Lin FY; Ho VA; Khiem HB; Trach DD; Bay PV; Thanh TC; Kossaczka Z; Bryla DA; Shiloach J; Robbins JB; Schneerson R; Szu SC
N Engl J Med; 2001 Apr; 344(17):1263-9. PubMed ID: 11320385
[TBL] [Abstract][Full Text] [Related]
27. Differential Killing of Salmonella enterica Serovar Typhi by Antibodies Targeting Vi and Lipopolysaccharide O:9 Antigen.
Hart PJ; O'Shaughnessy CM; Siggins MK; Bobat S; Kingsley RA; Goulding DA; Crump JA; Reyburn H; Micoli F; Dougan G; Cunningham AF; MacLennan CA
PLoS One; 2016; 11(1):e0145945. PubMed ID: 26741681
[TBL] [Abstract][Full Text] [Related]
28. A bivalent conjugate vaccine containing PspA families 1 and 2 has the potential to protect against a wide range of Streptococcus pneumoniae strains and Salmonella Typhi.
Kothari N; Kothari S; Choi YJ; Dey A; Briles DE; Rhee DK; Carbis R
Vaccine; 2015 Feb; 33(6):783-8. PubMed ID: 25545593
[TBL] [Abstract][Full Text] [Related]
29. A cluster-randomized effectiveness trial of Vi typhoid vaccine in India.
Sur D; Ochiai RL; Bhattacharya SK; Ganguly NK; Ali M; Manna B; Dutta S; Donner A; Kanungo S; Park JK; Puri MK; Kim DR; Dutta D; Bhaduri B; Acosta CJ; Clemens JD
N Engl J Med; 2009 Jul; 361(4):335-44. PubMed ID: 19625715
[TBL] [Abstract][Full Text] [Related]
30. Development of an anti-Salmonella typhi Vi ELISA: assessment of immunocompetence in healthy donors.
Ferry BL; Misbah SA; Stephens P; Sherrell Z; Lythgoe H; Bateman E; Banner C; Jones J; Groome N; Chapel HM
Clin Exp Immunol; 2004 May; 136(2):297-303. PubMed ID: 15086394
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of a standardised Vi poly-l-lysine ELISA for serology of Vi capsular polysaccharide antibodies.
Rigsby P; Beamish E; Hockley J; Atkinson E; Hitri K; Jones E; Yang JS; Qadri F; Bachtiar NS; Elias SC; Goel A; Mishra R; Dugyala R; Pasetti MF; Meiring JE; Mbewe M; Gordon MA; Pollard AJ; Logan A; Rijpkema S;
Biologicals; 2020 Jul; 66():21-29. PubMed ID: 32571662
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of alum-based adjuvant on the immunogenicity of salmonella enterica serovar typhi conjugates vaccines.
Tritama E; Riani C; Rudiansyah I; Hidayat A; Kharisnaeni SA; Retnoningrum DS
Hum Vaccin Immunother; 2018 Jun; 14(6):1524-1529. PubMed ID: 29359991
[TBL] [Abstract][Full Text] [Related]
33. Differential effects of BCG vaccine on immune responses induced by vi polysaccharide typhoid fever vaccination: an explorative randomized trial.
Blok BA; Arts RJW; van Crevel R; Aaby P; Joosten LAB; Benn CS; Netea MG
Eur J Clin Microbiol Infect Dis; 2020 Jun; 39(6):1177-1184. PubMed ID: 32065303
[TBL] [Abstract][Full Text] [Related]
34. S.Typhi derived OmpC peptide conjugated with Vi-polysaccharide evokes better immune response than free Vi-polysaccharide in mice.
Haque S; Sengupta S; Gupta D; Bhan MK; Kumar R; Khan A; Jailkhani B
Biologicals; 2019 Nov; 62():50-56. PubMed ID: 31606267
[TBL] [Abstract][Full Text] [Related]
35. Measurement and interpretation of Salmonella typhi Vi IgG antibodies for the assessment of adaptive immunity.
Parker AR; Bradley C; Harding S; Sánchez-Ramón S; Jolles S; Kiani-Alikhan S
J Immunol Methods; 2018 Aug; 459():1-10. PubMed ID: 29800575
[TBL] [Abstract][Full Text] [Related]
36. The Vi conjugate typhoid vaccine is safe, elicits protective levels of IgG anti-Vi, and is compatible with routine infant vaccines.
Thiem VD; Lin FY; Canh DG; Son NH; Anh DD; Mao ND; Chu C; Hunt SW; Robbins JB; Schneerson R; Szu SC
Clin Vaccine Immunol; 2011 May; 18(5):730-5. PubMed ID: 21411598
[TBL] [Abstract][Full Text] [Related]
37. Head-to-head comparison of humoral immune responses to Vi capsular polysaccharide and Salmonella Typhi Ty21a typhoid vaccines--a randomized trial.
Kantele A; Pakkanen SH; Karttunen R; Kantele JM
PLoS One; 2013; 8(4):e60583. PubMed ID: 23593253
[TBL] [Abstract][Full Text] [Related]
38. Development and evaluation of an enzyme-linked immunosorbent assay for serum Vi antibodies for detection of chronic Salmonella typhi carriers.
Losonsky GA; Ferreccio C; Kotloff KL; Kaintuck S; Robbins JB; Levine MM
J Clin Microbiol; 1987 Dec; 25(12):2266-9. PubMed ID: 3429619
[TBL] [Abstract][Full Text] [Related]
39. Protective activity of Vi capsular polysaccharide vaccine against typhoid fever.
Klugman KP; Gilbertson IT; Koornhof HJ; Robbins JB; Schneerson R; Schulz D; Cadoz M; Armand J
Lancet; 1987 Nov; 2(8569):1165-9. PubMed ID: 2890805
[TBL] [Abstract][Full Text] [Related]
40. Safety and immunogenicity of a Vi polysaccharide-tetanus toxoid conjugate vaccine (Typbar-TCV) in healthy infants, children, and adults in typhoid endemic areas: a multicenter, 2-cohort, open-label, double-blind, randomized controlled phase 3 study.
Mohan VK; Varanasi V; Singh A; Pasetti MF; Levine MM; Venkatesan R; Ella KM
Clin Infect Dis; 2015 Aug; 61(3):393-402. PubMed ID: 25870324
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
